Depression in the Elderly and Cerebral Amyloid Plaques: Characterization by [18F] AV-45 Affectives Symptoms and Amyloïd Plaques (ASAP)

• Status: Unknown status
• Trial end date: 2018-05-01
• Target enrollment: 0
• Participant gender: All

Summary

The primary objective of the study is to compare the brain amyloid load in fully, partially and non remitting depressed elderly patients at 8 weeks of antidepressant therapy, by using PET with [F18]AV45.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University Hospital, Tours

Criteria

Inclusion Criteria

• Adult 60 years or older

• Native language : french

• Study period > 7 years

• Major depression defined on the DSM-IV criteria assessed by MINI and HDRS score of 10 or over

• Affiliation to the national health insurance system

• Signed informed consent

Exclusion Criteria

• History of alcoholism or drug addiction

• MMSE less than or equal to 17

• Major depression with psychotic features

• Depressive episode resistant, patient who received two different antidepressants well conducted without significant therapeutic response

• Any current or past episode of mania, schizophrenia or any other psychotic disorder

• Any past history of stroke or Parkinson's disease

• Any current significant unstable illness

• Any past diagnosis of Alzheimer's disease

• Any current treatment by AcethylCholinesterae inhibitor, memantine or antidepressant therapy.

• Contraindications to MRI in patients with:

1. Metallic foreign body eye.

2. Any implanted electronic medical irremovably (pacemaker, neurostimulator, cochlear implants ...)

3. Metal heart valve,

4. Vascular clips formerly located on cranial aneurysm.

• Contraindications to antidepressants

• History of progressive disease that can affect the central nervous system such as uncontrolled diabetes, blood pressure greater than or equal to 180/100; chronic lung disease with hypoxia, head trauma with loss of consciousness greater than or equal to 15 minutes; brain surgery, encephalitis, recently treated cancer (<1 year), altered cerebral metabolism including subjects with stroke sequelae extended. Patients with lacunar stroke without thalamic or striatal may be included.